Drishti Shah1, Anuj Shah2, Xi Tan3, Usha Sambamoorthi3. 1. West Virginia University, Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA. Electronic address: drshah@mix.wvu.edu. 2. West Virginia University, Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA; Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, USA. 3. West Virginia University, Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
Abstract
BACKGROUND: In 2009, the FDA required a black box warning (BBW) on bupropion and varenicline, the two commonly prescribed smoking cessation agents due to reports of adverse neuropsychiatric events. We investigated if there was a decline in use of bupropion and varenicline after the BBW by comparing the percent using these medications before and after BBW. METHODS: We conducted a retrospective observational study using data from the Medical Expenditure Panel Survey from 2007 to 2014. The study sample consisted of adult smokers, who were advised by their physicians to quit smoking. We divided the time period into "pre-warning", "post-warning: immediate", and "post-warning: late." Unadjusted analysis using chi-square tests and adjusted analyses using logistic regressions were conducted to evaluate the change in bupropion and varenicline use before and after the BBW. Secondary analyses using piecewise regression were also conducted. RESULTS: On an average, 49.04% of smokers were advised by their physicians to quit smoking. We observed a statistically significant decline in varenicline use from 22.1% in year 2007 to 9.23% in 2014 (p value<0.001). In the logistic (Adjusted Odds Ratio=0.36, 95% CI=0.22-0.58) and piecewise regressions (Odds Ratio=0.64, 95% CI=0.41-0.99) smokers who were advised to quit smoking by their physicians were less likely to use varenicline in the immediate post-BBW period as compared to pre-BBW period. While the use of varenicline continued to be significantly low in the late post-BBW period (AOR=0.45, 95% CI=0.31-0.64) as compared to the pre-BBW period, the trend in use as seen in piecewise regression remained stable (OR=0.90, 95% CI=0.75-1.06). We did not observe significant differences in bupropion use between the pre- and post-BBW periods. CONCLUSION: The passage of the FDA boxed warning was associated with a significant decline in the use of varenicline, but not in the use of bupropion.
BACKGROUND: In 2009, the FDA required a black box warning (BBW) on bupropion and varenicline, the two commonly prescribed smoking cessation agents due to reports of adverse neuropsychiatric events. We investigated if there was a decline in use of bupropion and varenicline after the BBW by comparing the percent using these medications before and after BBW. METHODS: We conducted a retrospective observational study using data from the Medical Expenditure Panel Survey from 2007 to 2014. The study sample consisted of adult smokers, who were advised by their physicians to quit smoking. We divided the time period into "pre-warning", "post-warning: immediate", and "post-warning: late." Unadjusted analysis using chi-square tests and adjusted analyses using logistic regressions were conducted to evaluate the change in bupropion and varenicline use before and after the BBW. Secondary analyses using piecewise regression were also conducted. RESULTS: On an average, 49.04% of smokers were advised by their physicians to quit smoking. We observed a statistically significant decline in varenicline use from 22.1% in year 2007 to 9.23% in 2014 (p value<0.001). In the logistic (Adjusted Odds Ratio=0.36, 95% CI=0.22-0.58) and piecewise regressions (Odds Ratio=0.64, 95% CI=0.41-0.99) smokers who were advised to quit smoking by their physicians were less likely to use varenicline in the immediate post-BBW period as compared to pre-BBW period. While the use of varenicline continued to be significantly low in the late post-BBW period (AOR=0.45, 95% CI=0.31-0.64) as compared to the pre-BBW period, the trend in use as seen in piecewise regression remained stable (OR=0.90, 95% CI=0.75-1.06). We did not observe significant differences in bupropion use between the pre- and post-BBW periods. CONCLUSION: The passage of the FDA boxed warning was associated with a significant decline in the use of varenicline, but not in the use of bupropion.
Authors: Jill M Williams; Michael B Steinberg; Marc L Steinberg; Kunal K Gandhi; Rajiv Ulpe; Jonathan Foulds Journal: Expert Opin Pharmacother Date: 2011-06-06 Impact factor: 3.889
Authors: Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George Journal: J Clin Psychiatry Date: 2012-05 Impact factor: 4.384
Authors: Robert M Anthenelli; Chad Morris; Tanya S Ramey; Sarah J Dubrava; Kostas Tsilkos; Cristina Russ; Carla Yunis Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321
Authors: Eva Kralikova; Alexandra Kmetova; Lenka Stepankova; Kamila Zvolska; Rachel Davis; Robert West Journal: Addiction Date: 2013-05-13 Impact factor: 6.526
Authors: Sarah S Tonkin; Trevor F Williams; Leonard J Simms; Stephen T Tiffany; Martin C Mahoney; Robert A Schnoll; Paul M Cinciripini; Larry W Hawk Journal: Nicotine Tob Res Date: 2020-04-17 Impact factor: 4.244
Authors: Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Ravi J Desai; Meghan M Good; Alvaro San-Juan-Rodriguez; Andrew Henriksen; Francesca Cunningham; Inmaculada Hernandez; Chester B Good Journal: JAMA Netw Open Date: 2019-09-04
Authors: Rukshar K Gobarani; Jenni Ilomäki; Stephen Wood; Michael J Abramson; Billie Bonevski; Johnson George Journal: Addiction Date: 2022-06-11 Impact factor: 7.256